Clinical Trials Logo

Filter by:
NCT ID: NCT06152315 Recruiting - Clinical trials for Mitral Regurgitation

Mitral Splay Sign, Its Mechanism and Association With Severity of Regurgitation

Start date: January 1, 2023
Phase:
Study type: Observational

To study echocardiography splay sign in mitral regurgitation and its association with mitral regurgitation severity and doppler band artifact ('seagull cry').

NCT ID: NCT06148506 Recruiting - Clinical trials for HR+HER2- Advanced Breast Cancer

A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia

ValerEE
Start date: December 28, 2023
Phase:
Study type: Observational

This is а prospective, non-interventional, primary data collection cohort study to evaluate the clinical outcomes of the combination of ribociclib + ET and combination chemotherapy in the real-life setting in Russia. This study is observational in nature; it does not impose a therapy, diagnostic/therapeutic interventions or a visit schedule.

NCT ID: NCT06142357 Recruiting - Clinical trials for Moderate-to-severe Plaque Psoriasis

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis

SPARROW
Start date: December 29, 2023
Phase:
Study type: Observational

Multicenter, non-interventional, cohort study in pediatric patients with moderate to severe plaque-type psoriasis. Retrospective data collection is planned at patients' inclusion.

NCT ID: NCT06133699 Recruiting - Clinical trials for Testicular Germ Cell Tumor

Sentinel Lymph Node Biopsy in Stage AI-IIA Germ Cell Tumors

PITERLAND
Start date: November 8, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy of sentinel lymph node biopsy in stage AI-IIA germ cell tumors (seminoma/nonseminoma). The main questions it aims to answer are: - To evaluate relapse-free survival during the first two years after SLNB. - To estimate the percentage of patients who did not require adjuvant treatment after primary endoscopic SLNB. - Determine the microRNA expression profile in blood plasma, evaluate miRNAs as a potential prognostic and predictive factor in patients with testicular germ cell tumors. - Assess the correlation between computed tomography and positive lymph nodes on examination. Participants will undergo: - surgical treatment including orchofuniculectomy with simultaneous laparoscopic biopsy of the sentinel lymph node using indocyanine green dye with/without methylene blue dye. - 24 hours before the procedure, a radiopharmaceutical (RP) is injected into the spermatic cord, followed by SPECT to determine the regional sentinel lymph node(s). - The level of microRNA will be examined before surgery and 10 days after surgery.

NCT ID: NCT06124664 Recruiting - Clinical trials for Varicose Veins of Lower Limb

Study of Venous Outflow From the Lower Limbs in Patients With Pelvic Varicosities

Start date: May 4, 2023
Phase:
Study type: Observational

Compression therapy is basic treatment for chronic venous disease (CVD) of the lower limbs. Numerous studies have demonstrated the efficacy and safety of compression therapy in relieving symptoms such as pain, venous edema, leg heaviness and fatigue, as well as accelerating the healing of venous ulcers. It has been established that сompression therapy is indicated for patients with both minimally expressed manifestations of CVD and severe forms of the disease. At the same only one study has been conducted to assess the correction of venous outflow from the lower limbs and pelvis in patients with pelvic varicose vein (PVV) and pelvic congestion syndrome (PCS). However, the incidence of this pathology ranges from 15 to 30% in the female population. The cost to the healthcare system of treating these patients in the United States exceeds $2 billion. To date, the options and indications for compression therapy in patients with concomitant PVV and CVD have not been defined. The rational use of compression in this cohort of patients may contribute to the improvement of effective conservative treatment. In addition, inappropriate prescription of compression to patients with pelvic venous disease (which can be observed in real clinical practice) may discredit this simple, effective and safe therapeutic method. In addition, the research devoted to the problem of compression treatment of PVV will contribute to the development of new special compression products aimed at accelerating venous outflow from the pelvic organs. It can be assumed that this will serve as a stimulus for obtaining new data on the therapeutic effects of compression and create conditions for the creation of new technological directions in the production of compression knitwear.

NCT ID: NCT06121427 Recruiting - Chronic Hepatitis D Clinical Trials

Incidence of Viral Hepatitis D Relapses Upon Discontinuation of Bulevirtide in Patients With Chronic Hepatitis D and Negative HDV RNA

Start date: September 1, 2023
Phase:
Study type: Observational

This observational study will be conducted in patients with chronic co-infection with hepatitis B and D viruses, with negative PCR for HDV RNA in peripheral blood and no signs of active liver inflammation according to blood chemistry parameters, receiving background therapy with bulevirtide for more than 48 weeks and liver biopsy performed or prescribed to be performed as part of routine practice. After the patient has signed the Informed Consent, a portion of the liver biopsy collected as part of routine practice will be sent to the laboratory for PCR testing for HDV RNA, background therapy with bulevirtide will be interrupted, and the patient will be observed in the clinic in accordance with routine medical practice, but at least once times every 4 weeks, for timely detection of relapse of the hepatitis D and initiation of antiviral therapy. Once a relapse of viral hepatitis D is determined via the PCR HDV RNA, the patient's participation in the study will be terminated. The collected data will be analyzed to assess the probability of relapse-free over time. Separate tests will also be conducted for subgroups of patients based on covariates such as duration of previous background therapy with bulevirtide, duration of HDV suppression, use of any other concomitant antiviral therapy during bulevirtide treatment.

NCT ID: NCT06121089 Recruiting - Clinical trials for Colonic Neoplasms Malignant

Local Cecal Cancer - Optimization of Surgical Treatment

LoCCOSTe
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the clinical efficacy, safety, and oncologic outcomes of ileocecal resection (ICR) with D3 lymphadenectomy compared to standard right hemicolectomy(RHC) for cecal cancer.

NCT ID: NCT06120582 Recruiting - Hemophilia B Clinical Trials

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Start date: May 2, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this multicenter, two-stage, open-label study is to investigate the safety, immunogenicity, and efficacy of ANB-002 in subjects with hemophilia В. The study will have a dose-escalation design with elements of phase I/II seamless adaptive design.

NCT ID: NCT06119867 Recruiting - Colonic Neoplasms Clinical Trials

CompariSon Between the EuroPeAn and Japanese pathologiCal InvEstigation for Colon Cancer (SPACE)

SPACE
Start date: November 14, 2023
Phase: Phase 3
Study type: Interventional

In general, the European pathological examination method primarily relies on pathologists and does not require the involvement of surgeons. The Japanese pathological evaluation approach, on the other hand, involves the intervention of surgeons, particularly in the extraction of lymph nodes from fresh specimens and the assessment of specimen quality. Given that the Japanese pathological assessment method lacks systematic evaluation and there is currently no literature clearly demonstrating its diagnostic accuracy, the main objective of this study is to verify whether the diagnostic accuracy of the Japanese pathological investigation method is inferior to that of the European pathological evaluation method.

NCT ID: NCT06118619 Recruiting - Clinical trials for Respiratory Tuberculosis

A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis

Start date: June 1, 2022
Phase:
Study type: Observational

The main purpose of testing: To confirm the effectiveness and safety of the drug Ingaron when used in patients hospitalized at the research center for various reasons.